The activation of the stimulator of interferon genes (STING) pathway in the modulation of the immune system has gained much attention for immunosuppressive tumours such as GBM; however, they have been associated with high toxicity and premature degradation, causing limited efficacy [145]. This evidence concerns the gene STING1 and glioblastoma.